Amgen Inc.

Nuance Communications, Inc.

Sean P Brown

Yunxiao Li

Marc Vimolratana

Kexue Li

Joshua Taygerly

Julio Cesar Medina

Jonathan B Houze

Liusheng Zhu

Todd J Kohn

Ming Yu

Yingcai Wang

Brian Alan Lanman

Paul John Dransfield

Jiwen Liu

Vatee Pattaropong

Xianghong Wang

Markian Myroslaw Stec

Mike Elias Lizarzaburu

Ana Elena Minatti

Jonathan Dante Low

Paul E Harrington

Ana Zurisadai Gonzalez Buenrostro

Manuel Zancanella

Wang Shen

Matthew R Kaller

Zhihua Ma

Zice Fu

Alexander J Pickrell

Zhihong Li

Holger Quast

Nick A Paras

Michael J Schmitt

Kenneth S Harper

Xian Yun Jiao

Kate Ashton

Xiaohui Du

Xuelei Yan

Rajiv Sharma

Yosup Rew

Vladimir Sejnoha

Brian Stuart Lucas

Gunnar Evermann

An-Rong Li

Jinqian Liu

Carey Radebaugh

Stephen W Laverty

SuJen Lai

Marc W Regan

Ryan S LaSante

John R Watson

Peter K Lyons

Jeremy A Slater

Anthony B Reed

Daqing Sun

Jian Luo

Michael G Johnson

Felix Gonzalez Lopez De Turiso

Vu Van Ma

Alan C Cheng

Mario G Cardozo

Jason A Duquette

Gwenaella Rescourio

Gayathri Swaminath

Zhongyu Wang

Jie Zhang

Michael R Degraffenreid

Jiasheng Fu

YuMei Xiong

XianYun Jiao

Timothy Lynch

Yihong Li

Michael W Gribble, Jr

Victor Chen

Yongli Su

Jiang Zhu

Paweena Attayadmawittaya

Yong-Jae Kim

Margrit Schwarz

Charles L Ortiz, Jr

Jeffrey D Reagan

Michelle Akerman

Wei Qiu

Tiago Goncalves Cabaco

David Karl Bedke

Qiong Cao

Andrew R Wyatt

Salman Yojiro Jabri

Scott Preston Simonovich

Li Yang

Daniel Lin

Fares Jaradeh

Mike Lizarzaburu

Mike Elias Lizazaburu

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit Mcl-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stenoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 

Macrocyclic compounds that inhibit MCL-1 protein

Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer. 

Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists

Compounds that inhibits MCL-1 protein

A method, performed by at least one computer, the method comprising using the at least one computer to perform acts of accessing information specifying at least one user-specified condition specified by a user and at least one corresponding user-specified action, the user-specified action to be performed when the user-specified condition is met; determining whether the at least one user-specified condition is met; and when it is determined that the at least one user-specified condition is met, causing a virtual assistant executing on a mobile device different from the at least one computer to perform the at least one user-specified action.

Systems and methods for providing a virtual assistant

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Some embodiments provide techniques performed by at least one voice agent. The techniques include receiving voice input; identifying at least one application program as relating to the received voice input; and displaying at least one selectable visual representation that, when selected, causes focus of the computing device to be directed to the at least one application program identified as relating to the received voice input.

Systems and methods for providing a voice agent user interface

A system comprising at least one processor configured to perform: receiving a first request to access a first user profile of a first user from a first device configured to execute a first virtual assistant to interact with the first user; in response to receiving the first request, providing the first device with access to information in the first user profile so that the first virtual assistant is able to customize, based on the accessed information, its behavior when interacting with the first user; receiving a second request to access the first user profile from a second device configured to execute a second virtual assistant to interact with the first user; and in response to receiving the second request, providing the second device with access to the information so that the second virtual assistant is able to customize, based on the accessed information, its behavior when interacting with the first user.

Growing community of inventors

San Francisco, CA, United States of America

Sean P Brown